Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

  • Palafox, Marta
  • González-Pérez, Abel
  • Arribas, Joaquín
  • López Bigas, Núria
  • Serra, Violeta
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies., This study has been supported by the Susan G. Komen Foundation (CCR15330331) and by the Catalan Agency AGAUR (2017 SGR 540) [to V.S.]. V.S. received funds from the Instituto de Salud Carlos III: grants PI13/01714, CP14/00228, MV15/00041, CPII19/00033 and PI20/00892. M.P. received a Juan de la Cierva Grant from the Ministerio de Economía y Competitividad (FJCI-2015-25412), L.Mo. a grant from FI-AGAUR (2019 FI_B 01199), F.B-M. a grant from the Fundación Científica Asociación Española Contra el Cáncer (AECC_Postdoctoral17-1062) and M.S-G, a Marie Slodowska-Curie Innovative Training Networks PhD fellowship (H2020-MSCA-ITN-2015_675392). This work was supported by Breast Cancer Research Foundation (BCRF-19-08), Instituto de Salud Carlos III Project Reference number AC15/00062 and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181) and Asociación Española Contra el Cáncer (to J.A.). R.B.C. laboratory is supported by Breast Cancer Now (grant numbers: MAN-Q1 and MAN-Q2), NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007) and EdiREX Horizon 2020 grant No.731105. The xenograft program in the C.C. laboratory is supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). This work has been supported by NIH grants P30 CA008748 and RO1CA190642-01, the CDMRP grant BC171535P1, and the Breast Cancer Research Foundation [to M.S.]. A.P. received funds from Instituto de Salud Carlos III—PI16/00904 and PI19/01846, Breast Cancer Now—2018NOVPCC1294, Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research 19-20-26-PRAT, Fundació La Marató TV3 201935-30, the European Union’s Horizon 2020 research and innovation program H2020-SC1-BHC-2018-2020. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). C. S. Verma reports grants from MSD International and grants from Ipsen outside the submitted work.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype

  • Cuesta-Borràs, Estefania
  • Salvans, Cándida
  • Arqués, Oriol
  • Chicote, Irene
  • Ramírez, Lorena
  • Cabellos, Laia
  • Martínez-Quintanilla, Jordi
  • Mur-Espinosa, Alex
  • García-Álvarez, Alejandro
  • Hernando, Jorge
  • Tejedor, Juan Ramón
  • Mirallas, Oriol
  • Élez, Elena
  • Fraga, Mario F.
  • Tabernero, Josep
  • Nuciforo, Paolo
  • Capdevila, Jaume
  • Palmer, Héctor G.
  • Puig, Isabel
Tumor relapse is linked to rapid chemoresistance and represents a bottleneck for cancer therapy success. Engagement of a reduced proliferation state is a non-mutational mechanism exploited by cancer cells to bypass therapy-induced cell death. Through combining functional pulse-chase experiments in engineered cells and transcriptomic analyses, we identify DPPA3 as a master regulator of slow-cycling and chemoresistant phenotype in colorectal cancer (CRC). We find a vicious DPPA3-HIF1α feedback loop that downregulates FOXM1 expression via DNA methylation, thereby delaying cell-cycle progression. Moreover, downregulation of HIF1α partially restores a chemosensitive proliferative phenotype in DPPA3-overexpressing cancer cells. In cohorts of CRC patient samples, DPPA3 overexpression acts as a predictive biomarker of chemotherapeutic resistance that subsequently requires reduction in its expression to allow metastatic outgrowth. Our work demonstrates that slow-cycling cancer cells exploit a DPPA3/HIF1α axis to support tumor persistence under therapeutic stress and provides insights on the molecular regulation of disease progression., A.M.-E. received the support of a fellowship from “la Caixa” Foundation (100010434; code fellowship: LCF/BQ/DR20/11790017). H.G.P. was granted with a Miguel Servet contract (MSII14/00037). I.P. was supported by Fundación Científica Asociación Española Contra el Cáncer (FcAECC; code fellowships: INVES191PORT and INVES211004PUIG). The Vall d’Hebron Institute of Oncology (VHIO) would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the Fero Foundation for their funding support, and the Centro de Investigación Biomédica en Red Cáncer (CIBERONC). The authors acknowledge financial support from Agencia Estatal de Investigación (CEX2020-001024-S/AEI/10.13039/501100011033), the Instituto de Salud Carlos III (grants PI08/1356, PI20/00895, PI20/00897, and PI20/00968), TRANSCAN-TACTIC (grant AC15/00064), the European Union’s Horizon 2020 Research and Innovation program (EDIReX #731105), the EU/EFPIA Innovative Medicines Initiative (IMI) program (Horizon 2020-JTI-IMI2-2020-20-two-stage), “la Caixa” Foundation, and the Olga Torres Foundation (FOT)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2020-001024-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

  • Palafox, Marta
  • González-Pérez, Abel
  • Arribas, Joaquín
  • López Bigas, Núria
  • Serra, Violeta
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies., This study has been supported by the Susan G. Komen Foundation (CCR15330331) and by the Catalan Agency AGAUR (2017 SGR 540) [to V.S.]. V.S. received funds from the Instituto de Salud Carlos III: grants PI13/01714, CP14/00228, MV15/00041, CPII19/00033 and PI20/00892. M.P. received a Juan de la Cierva Grant from the Ministerio de Economía y Competitividad (FJCI-2015-25412), L.Mo. a grant from FI-AGAUR (2019 FI_B 01199), F.B-M. a grant from the Fundación Científica Asociación Española Contra el Cáncer (AECC_Postdoctoral17-1062) and M.S-G, a Marie Slodowska-Curie Innovative Training Networks PhD fellowship (H2020-MSCA-ITN-2015_675392). This work was supported by Breast Cancer Research Foundation (BCRF-19-08), Instituto de Salud Carlos III Project Reference number AC15/00062 and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181) and Asociación Española Contra el Cáncer (to J.A.). R.B.C. laboratory is supported by Breast Cancer Now (grant numbers: MAN-Q1 and MAN-Q2), NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007) and EdiREX Horizon 2020 grant No.731105. The xenograft program in the C.C. laboratory is supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). This work has been supported by NIH grants P30 CA008748 and RO1CA190642-01, the CDMRP grant BC171535P1, and the Breast Cancer Research Foundation [to M.S.]. A.P. received funds from Instituto de Salud Carlos III—PI16/00904 and PI19/01846, Breast Cancer Now—2018NOVPCC1294, Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research 19-20-26-PRAT, Fundació La Marató TV3 201935-30, the European Union’s Horizon 2020 research and innovation program H2020-SC1-BHC-2018-2020. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). C. S. Verma reports grants from MSD International and grants from Ipsen outside the submitted work.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

  • Giuntini, Fabio
  • Zacarias Fluck, Mariano F
  • Arnal, Magdalena
  • Pedretti, Flaminia
  • Grueso, Judit
  • Guzman Torres, Marta
  • González-Larreategui, Íñigo
  • Herencia Ropero, Andrea
  • Casacuberta-Serra, Sílvia
  • Serrano del Pozo, Erika
  • Rodríguez, Olga
  • Llop-Guevara, Alba
  • Balmaña, Judith
  • Nonell, Lara
  • Whitfield, Jonathan
  • Soucek, Laura
  • Serra, Violeta
Cancer; DNA damage; Omomyc, Càncer; Dany a l'ADN; Omomyc, Cáncer; Daño en el ADN; Omomyc, MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy., We acknowledge the kind support from the Vall d’Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – F.G., PFIS doctoral bursary); Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1 and Líneas Estratégicas PLEC2021-007959); Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509); EDIReX (H2020 INFRAIA 731105-2); the European Research Council (ERC-2023-ADG 101142260); the Spanish Ministry of Science and Innovation and the European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808); and the Fero Foundation for funding support.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Dppa3-hif1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype

  • Cuesta Borràs, E.
  • Salvans, C.
  • Arqués, O.
  • Tejedor Vaquero, Juan Ramón|||0000-0002-4061-9698
  • Fernández Fraga, Mario|||0000-0001-8450-2603
The authors acknowl- edge financial support from Agencia Estatal de Investigacio´ n (CEX2020- 001024-S/AEI/10.13039/501100011033), the Instituto de Salud Carlos III (grants PI08/1356, PI20/00895, PI20/00897, and PI20/00968), TRANSCAN- TACTIC (grant AC15/00064), the European Union’s Horizon 2020 Research and Innovation program (EDIReX #731105), the EU/EFPIA Innovative Medi- cines Initiative (IMI) program (Horizon 2020-JTI-IMI2-2020-20-two-stage), ‘‘la Caixa’’ Foundation, and the Olga Torres Foundation (FOT)., Cuesta-Borràs E., Salvans C., Arqués O., Chicote I., Ramírez L., Cabellos L., Martínez-Quintanilla J., Mur-Espinosa A., García-Álvarez A., Hernando J., Tejedor J.R., Mirallas O., Élez E., Fraga M.F., Tabernero J., Nuciforo P., Capdevila J., Palmer H.G., Puig I.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

  • Giuntini, Fabio
  • Zacarias Fluck, Mariano F
  • Arnal, Magdalena
  • Pedretti, Flaminia
  • Grueso, Judit
  • Guzman Torres, Marta
  • González-Larreategui, Íñigo
  • Herencia Ropero, Andrea
  • Casacuberta-Serra, Sílvia
  • Serrano del Pozo, Erika
  • Rodríguez, Olga
  • Llop-Guevara, Alba
  • Balmaña, Judith
  • Nonell, Lara
  • Whitfield, Jonathan
  • Soucek, Laura
  • Serra, Violeta
Cancer; DNA damage; Omomyc, Càncer; Dany a l'ADN; Omomyc, Cáncer; Daño en el ADN; Omomyc, MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy., We acknowledge the kind support from the Vall d’Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – F.G., PFIS doctoral bursary); Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1 and Líneas Estratégicas PLEC2021-007959); Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509); EDIReX (H2020 INFRAIA 731105-2); the European Research Council (ERC-2023-ADG 101142260); the Spanish Ministry of Science and Innovation and the European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808); and the Fero Foundation for funding support.